IFNB1 and melanoma: In melanoma patients treated with type I IFN therapy, neutrophils exhibit increased N1 markers, reduced chemokine receptor expression, and enhanced cytotoxic features, supporting the conserved role of IFN-β in driving N1 polarization across species [26].